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Abstract
Background Several vaccine and antibody candidates are currently in development for the prevention of lower respiratory 
tract infections caused by the respiratory syncytial virus (RSV).
Methods We searched MEDLINE, Embase, and SCOPUS and included model-based evaluations of RSV vaccinations. Two 
reviewers performed the selection, data extraction, and quality evaluation with EVIDEM. Cost-effectiveness (CE) estimates 
were converted to $US purchasing power parity (PPP), year 2018 values. Potential economic and epidemiological outcomes 
were summarised for maternal, infant, children, and elderly vaccinations. The PROSPERO identifier is CRD42019122570.
Results In total, 22 model-based studies were reviewed. On average, a potential 27% reduction in RSV hospitalisations in 
infants was projected for maternal vaccination and 50% for direct infant immunisation. The CE of maternal vaccination 
was $US1766–5857 PPP 2018/disability-adjusted life-years (DALYs) for Global Alliance for Vaccines and Immunisation 
(Gavi)-eligible countries. For England, the maximum cost-effective price of maternal vaccination was estimated at $US81.5 
PPP 2018. Infant vaccination was associated with higher CE ratios in low- and high-income settings. Vaccination of neonates 
born before the RSV season was the most cost effective in high-income settings. Higher values for vaccine effectiveness, 
duration of protection, and vaccine uptake increased the benefits. Due to indirect effects, the vaccination of school-age chil-
dren and a cocooning strategy were effective alternatives to protect infants, and the vaccination of children aged < 5 years 
had a beneficial impact on the elderly.
Conclusion RSV vaccines with anticipated characteristics may reduce a sizeable proportion of the RSV burden. The results 
are subject to uncertainty because of the limited epidemiological and clinical data. Data on RSV incidence and hospitalisa-
tion risk for granular age strata should be prioritised to facilitate the evaluation of RSV interventions and decision making.
Supplementary Information The online version contains 
supplementary material available at https ://doi.org/10.1007/s4027 
3-020-00991 -7.
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1 Introduction
Respiratory syncytial virus (RSV) is the most common cause 
of acute lower respiratory infection (ALRI), mainly in chil-
dren aged < 2 years [1–3]. The incidence of RSV infection is 
lower in the first weeks of life, possibly because of protection 
from transferred maternal antibodies in newborns, and peaks 
in infants up to 3 months of age [4]. By the end of the second 
year of life, most children have had an RSV infection [1]. A 
recent review of the global RSV burden estimated 1.4 mil-
lion (uncertainty range [UR] 1.2−1.7) RSV hospitalisations 
and 27,300 (UR 20,700–36,200) in-hospital deaths occurred 
in infants aged < 6 months in 2015. Hospital admissions in 
this group constituted 45% of global RSV hospitalisations 
in young children (aged 0–4 years), which were estimated 
at 3.2 million (UR 2.7–3.8) in 2015. The estimates showed 
that the incidence of RSV-ALRI in those aged 0–5 months 
was higher in low-income (117.2 per 1000) than in high-
income (66.1 per 1000) regions. In turn, hospital admission 
rates were reported to be much higher for high-income than 
for low-income countries. However, the small number of 
available studies limited the evidence on hospitalisations in 
low-income countries. The highest hospital admission rates 
 M. Treskova et al.
Key Points 
Given the absence of clinical evidence on the efficacy 
of the respiratory syncytial virus (RSV) vaccine and 
the duration of vaccine-induced immunity, the potential 
effects of vaccination are subject to uncertainty.
The current decision-analytic models suggest that mater-
nal, infant, and cocooning vaccinations with anticipated 
vaccine candidates may reduce a considerable proportion 
of RSV infections and hospitalisations in infants; the 
evidence for vaccination of the elderly is scarce.
Further economic evaluation of vaccination strategies is 
needed in the elderly and older children using dynamic-
transmission models.
were reported in infants aged < 6 months compared with 
other age groups across all geographies [5]. The influential 
factors of acquisition of RSV in children include birth before 
and shortly after the onset of RSV season and attendance 
of childcare facilities [4]. Severe RSV illness and compli-
cations requiring hospitalisation occur mainly in high-risk 
children. Premature infants and children with severe res-
piratory disease, congenital heart disease, cancer, cystic 
fibrosis, immune deficiency, or Down syndrome have been 
reported to be at increased risk for severe RSV infection [6, 
7]. Moreover, severe RSV disease during infancy presents a 
considerable risk for the development of recurrent wheez-
ing and asthma later in life [8, 9]. Asymptomatic or mild 
RSV reinfections are common in adult life [10], with more 
severe manifestation in immunocompromised individuals 
[11], patients with cardiopulmonary diseases, and the elderly 
[12]. The increasing evidence on RSV in the elderly suggests 
that the impact of the disease is non-negligible, particularly 
in people with underlying comorbidities, and is comparable 
to that of non-pandemic influenza [12–14].
Overall, RSV infection has been recognised as a disease 
with a considerable impact in the community and on hospital 
services that requires prevention in young children and older 
adults [14]. Currently, the only preventive strategy is passive 
immunisation since active immunisation is not yet available. 
Passive immunisation is attained by transferring antibodies 
to an unprotected individual [15]. In contrast, active immu-
nisation or vaccination leads the individual’s immune system 
to produce antibodies and build up cellular immunity [16]. 
While vaccination can induce a long-lasting immunity, pas-
sively induced immunity lasts for several weeks or months 
[15, 16]. The monoclonal antibody (mAb) palivizumab is 
used for RSV prevention but is usually restricted to infants 
with an underlying risk of severe RSV infection [1, 17]. 
No RSV vaccine has yet been licensed, but several vaccine 
candidates and mAbs are currently being tested in clinical 
trials [18]. Although vaccine effectiveness (VE) estimates 
are not yet available, decision-analytic models exploring 
the epidemiological and economic outcomes of potential 
RSV vaccination have been emerging. In this study, we 
summarised and critically appraised current evidence on 
the effectiveness and cost effectiveness of potential active 
vaccination strategies against RSV.
2  Methods
We performed a systematic review of decision-analytic mod-
els on active vaccination against RSV. The protocol of the 
review is published on PROSPERO (CRD42019122570).
The selection criteria were as follows: (1) model-based 
analyses; (2) original research or a systematic review; (3) 
focus on RSV vaccination; (4) reported additional costs and/
or additional health effects in terms of life-years gained, 
quality-adjusted life-years (QALYs), disability-adjusted life-
years (DALYs), life expectancy, reduction in RSV disease 
morbidity, reduction in RSV disease mortality; (5) either 
single- or multi-country study; (6) any language; and (7) 
publication since 2000.
Studies were excluded if they (1) investigated the epide-
miology, transmission, and natural history of RSV without 
modelling the impacts of vaccination; (2) estimated health-
care resource usage and costs of RSV infection only; (3) 
examined the effects of immunoprophylaxis (passive immu-
nisation) without consideration of any active immunisation.
We searched MEDLINE, Embase, and SCOPUS from 
2000 to the present (date of last search 22 October 2020), 
without restrictions. Two reviewers (MT, FPM) indepen-
dently performed screening, selection, data extraction, and 
quality evaluation of selected studies. In case of any disa-
greement, the third reviewer (STS) arbitrated to reach a con-
sensus. The search syntax and data extraction are described 
in the electronic supplementary material (ESM 1).
All studies included in the analysis underwent a qual-
ity assessment using the ‘Evidence and Value: Impact on 
DEcisionMaking’ (EVIDEM) instrument—‘Assessment 
of quality of economic evaluations’ [19]. The EVIDEM 
instrument evaluates (1) the quality of reporting in terms 
of completeness and consistency with cited sources and (2) 
the relevance and validity of evidence for decision making. 
We considered the EVIDEM instrument beneficial for the 
aims of this review because it provides an adaptable frame-
work and allows a thorough assessment with the scoring of 
both the relevance of evidence and the completeness of the 
reporting of the model-based evaluations. We adopted the 
‘parameters and estimates’ domain of EVIDEM to explore 
and evaluate the essential assumptions that directly govern 
the outcomes of the modelling of RSV transmission, the 
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effects and the costs of the interventions, and that are there-
fore critical for comparing the studies and interpreting the 
results. Studies that estimated only epidemiological effects 
of RSV vaccination (hereinafter epidemiological evaluation 
studies) were also subjected to the quality assessment of 
the applied methods. For these studies, we considered the 
absence of cost estimates as a limiting factor but not some-
thing that affected their relevance for decision making. Two 
evaluators (MT, FPM) independently completed the quality 
assessment across the 11 dimensions and assigned a score 
for each study, providing a rationale for the given score (1, 
2 for low and 3, 4 for high completeness of reporting and 
relevance/validity).
For the assessed economic evaluations, the results 
reported were time adjusted to the year 2018 by applying 
the country-specific consumer price indices and standardised 
to $US, year 2018 values using the purchasing power par-
ity (PPP) index and exchange rates for 2018 obtained from 
Organisation for Economic Co-operation and Development 
published data.
3  Results
The initial search identified 2491 records after removing 
duplicates across the databases. Repeated searches added 
514 records. Overall, 72 records were selected for abstract 
screening and eligibility assessment for full-text reading. 
After the full-text reading of 24 eligible studies, 22 were 
included in this review (Fig. 1) and subjected to data extrac-
tion and quality assessment.
3.1  Methodological Characteristics
Table 1 and Fig. 2 provide an overview of the methodologi-
cal characteristics of the reviewed studies.
3.1.1  Settings and Target Population
Most studies considered RSV vaccination in high-income 
countries: five in the USA [20–24], three in Spain [25–27], 
four in the Netherlands [28–31], two in England [32, 33], 
and one each in Australia [34], and Turkey [35]. Four stud-
ies used data from Kenya [3, 36–38]. Two studies explored 
RSV interventions in the countries supported by the Global 
Alliance for Vaccines and Immunisation (Gavi) [39, 40]. 
Eleven studies evaluated both economic and epidemiological 
impacts [20, 23, 25–30, 32, 35, 40], and 11 studies provided 
an evaluation of only epidemiological effects [3, 21, 22, 24, 
31, 33, 34, 36–39]. Nineteen studies evaluated interventions 
that target the reduction of RSV infections in infants and 
children aged < 5 years, and three studies examined vacci-
nation impact on morbidity and mortality in the elderly [20, 
24, 29]. The target population groups for vaccination strate-
gies covered in the review included (1) pregnant women, 
(2) newborns and infants, (3) young children, and (4) adults 
and the elderly.
3.1.2  Structure of Models
3.1.2.1 Dynamic and Static Modelling of Respiratory Syncy‑
tial Virus (RSV) Epidemiology Twelve studies used dynamic 
models (11 compartment models [21, 24–27, 31, 33, 34, 36–
38] and one individual-based model [3]), the remaining ten 
studies used static models. The dynamic models simulated 
the natural course of RSV infection, the transmission of the 
virus between the population groups, and, in some stud-
ies, healthcare utilisation. The static models concentrated 
mainly on the medically attended RSV cases.
3.1.2.2 The Natural History of RSV In the dynamic models, 
the natural history of RSV infection was approximated by the 
susceptible-infected-recovered-susceptible (SIRS) model, 
including the protection of newborns by maternal antibodies 
as described by Weber et al. [41]. Extensions of the model 
included a latent period (exposed compartment) of infec-
tion [21, 34], subsequent (milder) illness with reduced dura-
tion of infectiousness [24, 36], reduction of susceptibility 
[3, 36, 37] and infectivity in previously infected individuals 
[36, 37] or children aged > 10 years [34] and adults [24]. 
Pan-Ngum et al. [37] and Kinyanjui et al. [33] addressed in 
detail the uncertainty around the acquisition and duration 
of immunity after primary RSV infection and explored the 
impact of lifelong and short-term partial immunity after a 
primary RSV infection.
Most studies used either infections [3, 21, 24–27, 31] or 
hospitalisations [20, 23, 28, 33, 34, 36, 38–40] as epidemio-
logical ends. Eight studies distinguished between an asymp-
tomatic and symptomatic course of infection and modelled 
different severity of RSV disease within either a dynamic 
[33, 37] or static [22, 29, 30, 32, 35, 39, 40] framework. 
Pan-Ngum et al. [37] and Kinyanjui et al. [33] modelled 
hospitalised and non-hospitalised upper- and lower respira-
tory tract infections (URTI, LRTI) and severe LRTIs. Seven 
studies [22, 29, 30, 32, 35, 39, 40] used healthcare services 
to classify RSV infections into cases attended in outpatient 
care, hospital care, and emergency departments.
3.1.2.3 RSV Transmission and  Seasonality RSV transmis-
sion was simulated only in the dynamic models [3, 21, 
24–27, 31, 33, 34, 36–38], which used mixing between indi-
viduals (individual-based model [3]) or age-stratified com-
partments (compartment models) [21, 24–27, 31, 33, 34, 
36–38]. The dynamic models applied age-related mixing, 
and three studies [3, 36, 38] also simulated household- and 
community-related contacts.
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Within the dynamic models, seasonality of RSV epide-
miology was implemented mostly as a cosine function. The 
forced seasonal transmission was supplemented by demog-
raphy so that RSV incidence varied over the modelled years. 
Several static models [22, 28, 30, 32, 35] included calendar 
month-dependent RSV disease risk, and others did not rep-
resent seasonality.
The dynamic models, which included a wide range of 
age groups, simulated indirect protection of non-vaccinated 
groups provided by the direct vaccination. Static models 
either considered a birth cohort or an age-structured section 
of the population, e.g. children aged < 5 years and adults 
aged ≥ 50 years.
3.2  Vaccine Effects and Vaccination Strategies
3.2.1  Vaccine Uptake
Data on the interventions and assumptions about the 
vaccine effects are presented in Table 2. In 12 studies 
that evaluated vaccination of newborns or infants, vac-
cine uptake was assumed to be higher than 60%, with 
four assuming more than 90%. Vaccine uptake varied 
between 25 and 85%, with base-case values around 50% 
for pregnant women, and from 50 to 87% for the elderly. 
Meijboom et al. [29] set different values of vaccine cover-
age for the elderly, depending on the age and health risk 
Records identified through 
database searching (24.06.19)
after duplicates removed 
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Fig. 1  Flowchart of selection of studies for inclusion in the review. Excluded records are listed in ESM 3
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group. Most of the studies defined the vaccine uptake 
based on an assumption. Alternatively, the studies used 
observed influenza vaccine coverages for infants, children 
[22, 24, 30], and the elderly [20, 24], Bacillus Calmette-
Guérin vaccination for infant immunisation [40], and 
uptake estimates for maternal pertussis and influenza vac-
cines for the vaccination of pregnant women [22, 34]. For 
newborns and infants, the dosing schedule varied from 
one to three doses. One-dose schedules were assessed for 
vaccinations of pregnant women and the elderly.
3.2.2  Vaccine Effectiveness and Duration 
of Vaccine‑induced Immunity
Given the absence of clinical data on VE and duration 
of vaccine-induced immunity, the authors made various 
assumptions about vaccine characteristics. VE was imple-
mented as reduced susceptibility to RSV infection in the 
dynamic models and as a reduced proportion of hospitalisa-
tions or medically attended infections in the static models. 
Pan-Ngum et al. [37] and Kinyanjui et al. [33] considered a 
wide range of vaccine characteristics and modelled clinical 
endpoints in infants as a reduction in the risk of primary 
infection, the duration of infectivity, infectiousness, the risk 
of URTI, the risk of LRTI, and the risk of severe LRTI. 
Gessner [20] also explored possible VE against chronic 
obstructive pulmonary disease (COPD) in the elderly. VE 
varied from 25 to 100% among the studies and vaccine 
types. The baseline parameter ranged from 60 to 80% for 
the maternal vaccine, from 70 to 80% for the elderly, and 
from 50 to 100% for infants and children. Uncertainty meant 
that most studies reported results over a wide range of pos-
sible VE values.
For infant vaccination, 11 of 14 studies assumed 3–12 
months of vaccine-induced immunity. Cromer et al. [32] set 
no waning over 5 years, van Boven et al. [31] assumed full 
protection until the age of 5 years, and Meijboom et al. [30] 
evaluated no waning, plateau, and linear waning over 10 
years. Three studies [20, 24, 29] that evaluated vaccination 
in the elderly assumed that immunity lasted for one RSV 
season. Immunity in newborns due to maternal vaccination 
varied between 3 and 8 months. Additionally, Pan-Ngum 
et al. [37] and Kinyanjui et al. [33] considered potential 
interactions between vaccine-induced immunity and natu-
ral immunity due to maternal antibodies and modelled the 
effects of infant vaccine given in the presence of maternal 
antibodies that wane over time.
3.3  Epidemiological Estimates
Most incidence estimates represent infected individuals 
who seek healthcare. Eleven studies graphically illustrated 
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over the studied years in the modelled population. The 
approaches to estimating incidence among children were 
based on linkage of laboratory data to available admin-
istrative data [31, 32, 34], data from the hospital report-
ing system [3, 27, 33, 36–38], and observational studies 
[20, 21, 23, 28–30, 35]. Two studies that evaluated the 
intervention in Gavi-eligible countries obtained the data 
from a recent review [5], estimated the total burden of 
the disease for each of the countries, and used statistical 
modelling to address the lack of granularity in the data 
[39, 40]. Additionally, the dynamic models used a scaling 
factor that translated medically attended RSV infection 
identified in the surveillance systems to the infections in 
the model.
Table 3 presents the reported RSV incidence estimates 
without intervention and the resulting incidence reduction. 
The differences in reporting and the modelled age groups 
made it challenging to compare the incidence estimates 
across the studies. The studies that evaluated the protection 
of infants showed that RSV incidence was high in the first 5 
months of life and peaked in infants from 1 to 3 months of 
age. The studies that included medically attended RSV infec-
tions reported that the proportion of cases treated in out-
patient care was substantial. Three studies that considered 
vaccination in the elderly did not represent the age-specific 
incidence of RSV sufficiently to provide a summary. Mei-
jboom et al. [29] reported that the hospitalisation numbers 
increased with age and health risk and were highest in the 
elderly aged ≥ 85 years.
3.4  Economic Evaluation
This review included 11 economic assessments. Six evalu-
ated infant vaccination: (1) three Spanish studies estimated 
total costs based on dynamic models [25–27] and (2) three 
cost-effectiveness analyses based on static models (two from 
the Netherlands [28, 30] and one from the USA [23]).
Three studies (one from England [32], one from Turkey 
[35], and one including 72 Gavi-eligible countries), con-
ducted cost-effectiveness analyses of passive immunisation 
of infants and pregnant women separately and in combina-
tion, using static models. Two studies provided cost-effec-
tiveness analyses of elderly vaccination based on static 
models: one from The Netherlands [29] and one from the 
USA [20]. In the majority of studies, the comparator was 
no vaccination. Régnier et al. [23], Cromer et al. [32], and 
Rainisch et al. [22] also included passive immunisation with 
the mAb palivizumab in the analyses. Other studies did not 
include current immunoprophylaxis in the analysis, although 
four described it as an existing prevention [24, 28, 30, 35]. 
Six studies used the perspective of a healthcare provider [20, 
23, 28, 29, 32, 40], two of which also considered the soci-
etal perspective [23, 28], and two studies [30, 35] reported 
only the societal perspective. Three studies did not report 
the perspective [25–27].
Three studies evaluated economic outcomes other than 
the incremental cost-effectiveness ratio (ICER). Cromer 
et al. [32] compared strategies using maximum cost-effective 
price per fully protected person, Bos et al. [28] calculated 
Yes No
Yes No




















Fig. 2  Overview of selected methodological characteristics of the reviewed studies (n = 22). nr not reported, y year, “Other” group includes: 
Women/Infant/Children, Elderly/Children, Women/household
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break-even costs, and Meijboom et al. [30] reported maxi-
mum total vaccination costs per individual. Li et al. [40] 
performed a comprehensive comparative analysis of the 
cost effectiveness of maternal and infant interventions for 
72 Gavi-eligible countries, defining an optimal strategy for 
a range of willingness-to-pay (WTP) values for each country.
Six cost-effectiveness analyses used QALYs gained due 
to intervention: two in the elderly [20, 29] and four in chil-
dren [23, 29, 32, 35]. In children, Cromer et al. [32] and 
Meijboom et al. [30] set QALY loss for an RSV disease 
based on healthcare services: general practitioner (GP)-
treated RSV (0.01), hospitalisation (0.04), and admission 
to an intensive care unit or chronic respiratory morbidity 
(0.08). Meijboom et al. [30] obtained these values from the 
study by The Dutch National Institute for Public Health and 
the Environment, which assigned QALY decrements of 0.01 
to bronchi(oli)tis, 0.04 to pneumonia, and 0.08 to asthma. 
Pouwels et al. [35] set the disutility for a GP-treated RSV 
infection at 0.16 and for a hospital-treated RSV infection 
at 0.43 per day, with an average duration of infection of 14 
days. The authors referred to a Canadian study that derived 
health states for RSV in children and adults using time trade-
off and best–worst scales [42]. Régnier et al. [23] estimated 
a QALY loss per RSV hospitalisation of 0.01 and a QALY 
loss of 0.005 and 0.008 for mild and severe cough (duration 
10 days), respectively. The authors obtained the values from 
a study that estimated health states for pertussis infections 
[43]. For the elderly, Gessner [20] and Meijboom et al. [29] 
reported utilities that the patients experience during RSV 
treated in outpatient care (0.46 per day for 1 week) and inpa-
tient care (0.35 per day for 3 weeks).
3.5  Quality Assessment
Using the EVIDEM score of 3 or 4 as an indicator, we con-
sidered 18 of 22 studies as complete in reporting and 14 
studies as relevant for decision making. Four studies [21, 
25–27], which were more methodological papers than evalu-
ations, were given a lower score for relevancy for decision 
making. Overall, the studies that included a dynamic-trans-
mission model, examined uncertainty surrounding VE, and 
evaluated a wide range of vaccination scenarios were scored 
more highly. The final EVIDEM forms with comments and 
scores are available in ESM 2. Figure 3 presents the studies 
evaluated, categorising them by target group, type of analy-
sis, and relevance for decision making.
3.6  Results of the Epidemiological and Economic 
Evaluations
Table 3 presents the estimated reduction of RSV burden 
and the study conclusions. No clinical evaluation of VE and 
duration of vaccine-induced immunity is yet available, so 
all reported estimates of reduction of the RSV disease bur-
den should be considered as potential and theoretical. The 
absolute and relative potential reductions in the number of 
hospitalisations were the most frequently used epidemio-
logical outcomes reported in the selected studies. Figure 4 
illustrates the reported percentage reduction in the outcomes 
relative to the ‘no vaccination’ scenario. Table 4 presents the 
results of economic analyses. In the following sections, we 
summarise the results of the studies with EVIDEM scores 
of 3 or 4, indicating higher relevance for decision making.
3.6.1  Vaccination of Pregnant Women (Maternal 
Vaccination)
In a high-income country setting (Australia), and using a 
dynamic model, Hogan et al. [34] simulated the potential 
effects of a wide range of scenarios of maternal vaccina-
tion, varying the VE and duration of vaccine-induced immu-
nity on RSV hospitalisations in infants aged 0–2 and 3–5 
months. The percentage reduction in hospitalisations ranged 
from 6 to 51% and was higher for infants aged 3–5 months. 
The authors reported a 26% reduction in those aged 0–2 
months and a 40% reduction in those aged 3–5 months for 
the scenario defined by 80% VE, 50% vaccine uptake, and 
6-months of vaccine-induced immunity. The scenario with 
higher effectiveness (90%) and coverage (70%) resulted in 
the most substantial estimated reduction in hospitalisations, 
of 51% in children aged < 3 months and 63% in those aged 
3–5 months. Lower VE and coverage resulted in 10 and 
21% reductions in hospitalisations in these groups, respec-
tively. A reduced duration of vaccine-induced immunity of 
3 months did not bring additional beneficial health outcomes 
in infants aged > 3 months. Additionally, the authors pointed 
out that the impact of maternal vaccination in children aged 
> 6 months (given that the maximum duration of vaccine-
induced immunity was 6 months) was negligible, indicating 
a small herd effect.
The results of van Boven et al. [31] from The Netherlands 
support the inference of Hogan et al. [34] about the negligi-
ble indirect benefits of maternal vaccination in groups other 
than infants. The study reported a potential 27% decrease 
in the infection attack rate as a result of vaccinating 50% of 
pregnant women with a 50% effective vaccine and assumed 
duration of protection of 6 months.
In contrast, Brand et al. [38] showed possible indirect pro-
tection of newborns and infants via a cocooning vaccination 
strategy, that is via vaccinating pregnant women and their 
household members. The study was based on a dynamic-
transmission model that captured the transmission within 
households and in the community in a low-income country 
setting of Kenya. For 75% household coverage, the authors 
reported a potential 50% reduction in RSV hospitalisation in 
infants even if the maternal vaccine fully protected newborns 










































































Fig. 3  Overview of included studies by vaccination target, relevance 
for decision making, and type of evaluation. Economic evaluations 
reported monetary outcomes of the intervention. Epidemiological 
evaluations estimated epidemiological effects of vaccination without 
evaluation of costs. Completeness of reporting and relevance for deci-
sion making was assessed using EVIDEM: (1) scores 3 and 4 indicate 
higher relevance and (2) scores 1 and 2 indicate lower relevance. The 
studies are represented as the name of the first author, year of publi-
cation and country (as three-letter country code). Gavi Global Alli-
ance for Vaccines and Immunisation 
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U56%+U38% VE80%+mAB51%, D90d+D150d in infants [Rainisch, 2020, USA, nHI, 4/3]
U85%, VE60%, D8m in infants [Pouwels, 2016, TUR, nHI, 4/3]**
Eff.U 100%+Eff.U100%, D90d, in infants [Brand, 2020, KEN, HI, 4/4]
Eff.U 100%+Eff.U100%, D75d, in infants [Brand, 2020, KEN, HI, 4/4]
Eff.U 50%+Eff.U100%, D75d, in infants [Brand, 2020, KEN, HI, 4/4]
Eff.U 100%+Eff.U75%, D75d, in infants [Brand, 2020, KEN, HI, 4/4]
Eff.U 50%+Eff.U75%, D75d, in infants [Brand, 2020, KEN, HI, 4/4]
Combined maternal and infant vaccination
U55−87%, VE100%, >60 yo, at risk D1seas [Meijboom (b), 2013, NED, nHI, 3/2]**
U55−87%, VE100%, >60 yo, D1seas [Meijboom (b), 2013, NED, nHI, 3/2]**
U55−87%, VE40%, >60 yo, at risk D1seas [Meijboom (b), 2013, NED, nHI, 3/2]**
U55−87%, VE40%, >60 yo, D1seas [Meijboom (b), 2013, NED, nHI, 3/2]**
Elderly vaccination 
U75%, VE60%,  <5yo, D1seas, in >50yo  [Yamin, 2016, USA, HI, 4/4]
U75%, VE60%, <5yo, D1seas, in <5yo  [Yamin, 2016, USA, HI, 4/4]
U100%, VE100%, school, D6m, in gen pop [Poletti, 2015, KEN, HI, 4/4]
U100%, VE100%, school, D6m, in infants [Poletti, 2015, KEN, HI, 4/4]
Chlidren vaccination 
U100%, VE50%, D6mo−4yo, in 5−9yo [van Boven, 2020, NED, HI, 4/3]
U100%, VE50%, D6mo−4yo, in 1−4yo [van Boven, 2020, NED, HI, 4/3]
U100%, VE50%, D6mo−4yo, in infants [van Boven, 2020, NED, HI, 4/3]
U69%, VE50%, D12m hl, in infants [Regnier, 2013, USA, nHI, 4/2]
U71%,80%, mAB80%, D150d, in infants [Rainisch, 2020, USA, nHI, 4/3]
U85%, VE60%, at2&4mo, D2y, in infants [Pouwels, 2016, TUR, nHI, 4/3]**
U100%, VE100%, at 3m, D6m, in infants [Poletti, 2015, KEN, HI, 4/4]
U90%, VE70%, D1y, in <5yo [Pan−Ngum, 2017, KEN, HI, 4/4]
U69%, VE50%, D12m hl,  in infants [Régnier, 2013, USA,nHI, 4/2]
U96%, VE30%,60%,75%, at 0,1,3mo, D const, in infants [Meijboom(a), 2012, NED,nHI, 4/3]**
U96%, VE30%,60%,75%, at 0,1,3mo, D linear, in infants [Meijboom(a), 2012, NED,nHI, 4/3]**
U96%, VE30%,60%,75%, at 0,1,3mo, D plateau, in infants [Meijboom(a), 2012, NED,nHI, 4/3]**
U°, mAB70%, D6m, <1yo [Li, 2020, Gavi, nHI, 4/4]**
U90%, VE50−70%, at2&4mo, D1y, in <5yo [Kinyanjui, 2020, ENG,HI, 3/4]
U70%, VE100%, at 5m, D6m, in infants [Kinyanjui, 2015, KEN,HI, 4/4]
U70%, VE100%, at 10m, D6m, in infants [Kinyanjui, 2015, KEN,HI, 4/4]
U70%, VE100%, at 6m, D6m, in infants [Kinyanjui, 2015, KEN,HI, 4/4]
U100%, VE100%, D5y, in infants [Cromer, 2017, UK, nHI, 4/3]
U100%, VE50%, D from 6m, in infants [Bos, 2007, NED, nHI, 4/2]**
U100%, VE100%, D from 1m, in infants [Bos, 2007, NED, nHI, 4/2]**
U100%, VE70%, D from 6m, in infants [Bos, 2007, NED, nHI, 4/2]**
U100%, VE70%, D from 1m, in infants [Bos, 2007, NED, nHI, 4/2]**
U100%, VE90%, D from 3m, in infants [Bos, 2007, NED, nHI, 4/2]**
U100%, VE70%, D from 3m, in infants [Bos, 2007, NED, nHI, 4/2]**
Infant vaccination
U50%, VE505, D6m, in infants [van Boven, 2020, NED, HI, 4/3]
U85%, VE60%, D, in infants [Pouwels, 2016, TUR, nHI, 4/3]**
U60%, VE100%, D8m, in infants [Poletti, 2015, KEN, HI, 4/4]
U100%, VE100%, D8m, in infants [Poletti, 2015, KEN, HI, 4/4]
U50%, VE100%, D3m, in infants [Pan−Ngum, 2017, KEN, HI, 4/4]
U°, VE70%, D5m, <1yo [Li, 2020, Gavi, nHI, 4/4]**
U30%, VE70%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U30%, VE70%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U70%, VE90%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U70%, VE90%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D4m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D4m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D3m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D3m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE90%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE90%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE70%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE70%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE60%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE60%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U70%, VE80%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U70%, VE80%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U30%, VE80%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U30%, VE80%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D6m, in 3−5 mo [Hogan, 2017, AUS, HI, 4/4] 
U50%, VE80%, D6m, in 0−2 mo [Hogan, 2017, AUS, HI, 4/4] 
U69−100%, VE60%, D5m, in infants [Baral, 2020, Gavi, nHI, 4/3]
Maternal vaccination
0 25 50 75 100













Fig. 4  The estimated relative reduction in respiratory syncytial virus 
(RSV) infections and RSV-caused hospitalisations. Each strategy 
is defined by vaccine uptake, U vaccine effectiveness, VE vaccine-
induced duration of immunity, D (hl. half-life, seas season), and a 
group of the population where the reported effect is observed (e.g. 
in infants). The study is denoted by the first author, year, three-letter 
country abbreviation, inclusion of herd immunity (HI herd immunity 
included, nHI herd immunity not included), and EVIDEM scores 
for completeness of reporting and relevance for decision making. 
Note: Baral et  al. [39] summed the results over 73 Gavi-supported 
countries, reported for the year 2035, the vaccine uptake is country 
specific, on average 69% but projected to increase to 95%. Bos et al. 
[28] varied the month of start of the vaccine-induced immunity. 
Brand et al. [38]: the vaccination strategy is to vaccinate the pregnant 
women as part of their prenatal contact and the household cohabit-
ants at the birth of a baby. Kinyanjui et al. [36] reported the results 
of vaccinating at different ages. Li et al. [40] summed the results over 
72 Gavi-supported countries for the year 2022, U° country-specific 
coverage of Bacillus Calmette-Guérin vaccination in 2016. Meij-
boom et al. [30] reported the results of three-dose vaccination policy 
with VE given for the first, second, and third dose. The vaccine wan-
ing period was 10 years. Régnier et al. [23] was set in the base-case 
vaccine-induced duration with a half-life of 12 months. Poletti et al. 
[3] reported the outcomes for annual vaccination over 10 years. Only 
results are included that were reported or could be calculated. The 
studies by Acedo et al. [25, 26], Jornet-Sanz et al. [27], and Nugraha 
et  al. [21] could not be included. Not all results that were reported 
in the study are presented in the figure. The values that are graphi-
cally presented are not included because of the absence of an actual 
number, and this refers to the studies by Cromer et al. [32], Kinyanjui 
et al. [36], Pan-Ngum et al. [37], Poletti et al. [3], and Yamin et al. 
[24]. “Double asterisk” calculated in the review. Gavi Global Alli-
ance for Vaccines and Immunisation
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Table 4  Economic estimates reported in the included economic evaluations (in $US PPP 2018) (n = 11)
Study, country, year Evaluation Economic outcome $US PPP 2018
Acedo et al. [25, 26], Spain, 2010 Vaccination of newborns with two 
booster doses
Cost saved 3,816,392.93
Acedo et al. [25, 26], Spain, 2010 Vaccination of newborns with two 
booster doses
Cost saved 3,816,392.93
Bos et al. [28], The Netherlands, 
2007
Vaccination of infants born in 
January; VE 70%, protection 
from 3 mo onwards
Cost per hospitalisation averted 5353.15
Vaccination of infants born in 
January; VE 70%, protection 
from 3 mo onwards
Break-even costs 45.66
Cromer et al. [32], England (UK), 
2017
Infant (base case without seasonal 
restrictions)
Maximum cost-effective price per 
fully protected person
289.65
Newborn (base case without sea-
sonal restrictions)
122.20
Maternal (base case without sea-
sonal restrictions)
81.46
Combined a newborn and infant 
programme
371.11
Protect only neonates born in 
November (the most cost-effec-
tive strategy)
331.89
Gessner [20], USA, 2000 Elderly ≥ 65 y; without a 10% VE 
against COPD
Cost per death prevented 207,270.95
Elderly ≥ 65 y; without a 10% VE 
against COPD
Cost per year of life gained 11,726.49
Elderly ≥ 65 y; without a 10% VE 
against COPD
Cost per QALY gained 8592.99
Elderly ≥ 65 y; with a 10% VE 
against COPD
Cost per death prevented 136,440.70
Elderly ≥ 65 y; with a 10% VE 
against COPD
Cost per year of life gained 7841.79
Elderly ≥ 65 y; with a 10% VE 
against COPD
Cost per QALY gained 6886.30
Jornet-Sanz et al. [27], Spain, 2017 Vaccination of 80% newborns, VE 
100%
Cost saved (calculated by 
reviewer)
18,076,645.59
Vaccination of 20% newborns, VE 
100%
7,952,622.57
Li et al. [40], 72 Gavi-eligible 
countries, 2020
Maternal vaccination: VE 70%, 
duration 5 mo
Average cost per DALY averted 1766 (Angola) – 5857 (Vietnam)
Infant immunisation with mAb: 
effectiveness 70%, duration 6 mo
Average cost per DALY averted 3260 (Angola) − 8198 (Vietnam)
Meijboom et al. [30], The Nether-
lands, 2012
Infant vaccination: 3 doses, 0, 1, 
3 m., no waning VE
Cost per QALY gained 48,566.79
Infant vaccination: 3 doses, 0, 1, 
3 mo, plateau waning VE
Cost per QALY gained 55,131.41
Infant vaccination: 3 doses, 0, 1, 
3 mo, linear waning VE
Cost per QALY gained 73,407.08
Infant vaccination: 3 doses, 0, 2, 
4 mo, no waning VE
Cost per QALY gained 58,178.30
Infant vaccination: 3 doses, 0, 2, 
4 mo, plateau waning VE
Cost per QALY gained 62,469.84
Infant vaccination: 3 doses, 0, 2, 
4 mo, linear waning VE
Cost per QALY gained 83,357.13
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for a short period of 3 months. Increasing the household 
coverage up to 100% would induce an additional reduction 
of 5% in RSV hospitalisations.
Among the other two studies based on the data from 
Kenya, Pan-Ngum et al. [37] showed that the majority of 
modelled vaccination profiles with a maximum duration 
of protection of 6 months resulted in a 7–15% reduction in 
hospitalisations in children aged < 5 years. Poletti et al. [3] 
modelled the effect of maternal vaccination as an increase 
of duration of natural immunity in newborns derived from 
maternal antibodies. Vaccination was assumed to prolong 
the 4 months of natural maternal protection up to 5, 6, and 
8 months. Assuming 8 months of immunity in 100% of pro-
tected newborns in the modelled cohort, the authors pre-
dicted a 31.5% potential reduction in RSV infant infections.
Using a static model without herd effects in the USA, Rai-
nisch et al. [22] evaluated the introduction of maternal vacci-
nation in addition to within-season passive immunisation of 
high-risk infants with palivizumab as one of three strategies. 
The base-case scenario was defined as 80% VE, 56% vac-
cine uptake, and 90 days of vaccine-induced immunity for 
maternal vaccination and 51% effectiveness, 38% coverage, 
and 150 days of protection for palivizumab. Compared with 
no intervention, this scenario resulted in a 14% reduction 
in RSV-associated LRTIs attended in outpatient clinics, a 
13% reduction in emergency department visits, and a 25% 
reduction in hospital admissions.
Two further studies [32, 35] estimated the epidemio-
logical and economic outcomes of maternal vaccination 
using static models. In the study by Pouwels et al. [35] 
in Turkey, a 17% reduction in infant hospitalisations was 
estimated due to maternal vaccination assuming 60% VE, 
85% vaccine coverage, and 8 months of protection. The 
estimated cost effectiveness of this strategy was $US57,195 
PPP 2018 per QALY gained. Cromer et al. [32] estimated 
an 80% potential reduction in outpatient-attended RSV 
infections in England, averting around 1.5 RSV-attributable 
hospital admissions per 100 births and implying a 43% 
QALY gain. They showed that maternal vaccination with 
70% effectiveness and 3 months of protection could be cost 
effective if the price of the vaccine was set at $US81.5 PPP 
2018 or lower.
Table 4  (continued)
Study, country, year Evaluation Economic outcome $US PPP 2018
Meijboom et al. [29], The Nether-
lands, 2013
Vaccination of elderly ≥ 60 y 
cohort; VE 40%
Cost per QALY gained 189,282.90
Vaccination of elderly ≥ 60 y 
cohort; VE 100%
Cost per QALY gained 72,700.12
Vaccination of elderly ≥ 60 y 
cohort; VE of 40%; vs. WTP of 
€50,000/QALY
Maximum total vaccination costs 
per individual
20.68
Vaccination of elderly ≥ 60 y 
cohort; VE 100%; vs. WTP of 
€50,000/QALY
52.25
Pouwels et al. [35], Turkey, 2016 2+4 mo infant vaccination Cost per QALY gained 49,018.00
Maternal vaccination Cost per QALY gained 57,194.74
Combined 2+4 mo infant and 
maternal programme
Cost per QALY gained 58,152.10
Régnier et al. [23], USA, 2013 Vaccination of one cohort (4.2 
million live births)/healthcare 
system perspective
Cost per hospitalisation averted 21,551.54
Vaccination of one cohort (4.2 
million live births)/healthcare 
system perspective
Cost per year of life gained 242,943.86
Vaccination of one cohort (4.2 
million live births)/healthcare 
system perspective
Cost per QALY gained 104,993.52
Vaccination of one cohort (4.2 
million live births)/societal 
perspective
Cost per QALY gained 73,196.79
The outcomes are vs. no intervention
COPD chronic obstructive pulmonary disease, DALY disability-adjusted life-year, Gavi Global Alliance for Vaccines and Immunisation, mAb 
monoclonal antibody, mo month old, PPP purchasing power parity, QALY quality-adjusted life-year, VE vaccine effectiveness, WTP willingness-
to-pay, y year
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Two static-model-based evaluations explored the effects 
of maternal vaccination in Gavi-eligible countries. The 
structure of the models, underlying incidence data, and 
assumed vaccine-related parameters were similar between 
the studies. Li et al. [40] reported the results for 2022 for 
72 countries and projected the potential prevention of 1.2 
million RSV cases, 104,000 RSV hospitalisations, 3000 
deaths, and 98,000 DALYs (3% discounted) for maternal 
vaccination (VE of 70% and 5 months of protection). Fur-
ther, between 2023 and 2035, Baral et al. [39] projected a 
potential reduction of, on average, 11.3 million cases, more 
than 3.4 million RSV hospitalisations, 150,000 deaths, and 
10.3 DALYs (not discounted) reached through maternal 
vaccination (VE of 60% and 5 months of protection) with 
increased coverage in 73 Gavi-supported countries. The eco-
nomic evaluation by Li et al. [40] provided an estimation 
of cost-effectiveness ratios ($US/DALY averted) compared 
with no intervention for each country. For a vaccine price 
of $US3.10 PPP 2018, the reported estimates vary from 
$US1766 PPP 2018 per DALY for Angola to $US5857 
PPP 2018 per DALY for Vietnam. The study shows that, if 
the WTP value is more than $US1000 per DALY averted, 
a change from the current situation to the introduction of 
maternal vaccination could be optimal.
3.6.2  Infant Vaccination
Most of the studies included in this review evaluated active 
vaccination of children aged < 1 year. Ten studies [3, 22, 
30–33, 35–37, 40] were considered relevant for decision 
making (see Table 3 and Fig. 3) and are presented in this 
section. Three [3, 36, 37] of them conducted dynamic mod-
elling of routine infant immunisation based on Kenyan hos-
pital data and, as such, incorporated herd immunity. Poletti 
et al. [3] estimated that routine vaccination of all infants 
aged 3 months with a vaccine providing full protection over 
6 months led to a 41.5% decrease in RSV primary infec-
tions in infants (see Fig. 4). Pan-Ngum et al. [37] reported 
a median reduction of ≥ 50% RSV-associated hospitalisa-
tions within a year if 90% of infants were vaccinated at 2 
and 4 months of age. Kinyanjui et al. [36] investigated the 
optimal age to vaccinate children aged < 1 year, aiming to 
increase reductions in RSV hospitalisations. Over 60% of 
hospitalisations were averted with 70% vaccination coverage 
at 6 months of age. The most considerable reduction (80%) 
was achieved when infants were vaccinated at 10 months, 
and the smallest effect (40% reduction) was obtained with a 
vaccine administered at 5 months.
Poletti et al. [3] noticed that infant vaccination had little 
impact on infections in other age groups. However, Pan-
Ngum et al. [37], who considered a more extensive array of 
vaccine characteristics, proposed that a substantial reduc-
tion of hospitalisations was due to the vaccine-induced 
shortening of the duration of infection and decreasing infec-
tiousness. They pointed out the importance of herd protec-
tion with the decrease of RSV transmission in the age group 
at risk. Kinyanjui et al. [36] confirmed the essential benefits 
of the indirect effects of vaccination and proposed that thor-
ough consideration of vaccine-induced herd immunisation 
influenced the optimal allocation of the vaccine.
Kinyanjui et  al. [33] applied two dynamic models 
described in Pan-Ngum et al. [37] in England and Wales. 
They explored the effects on RSV hospitalisations of chil-
dren aged < 1 and < 5 years associated with vaccinating 
infants at different ages and using different dose regimens. 
The authors projected a potential rapid reduction (within 
a year) and further stabilisation of incidence at 50% of the 
pre-vaccination level. The projected estimates were similar 
to those reported by Pan-Ngum et al. [37] for Kenya.
Van Boven et al. [31] evaluated the vaccination of infants 
in The Netherlands, but, in contrast, applied lower VE with 
a more extended period of protection (up to the age of 4 
years). The study showed a potential 30% reduction of 
the infection attack rate in infants. It also projected a 28% 
decrease in infections in those aged 1–4 years and an 8% 
reduction in those aged 5–9 years. These potential effects 
in older children could stem from the assumption of a long-
lasting vaccine-induced immunity coupled with the indirect 
effects of the vaccination. The authors did not further inves-
tigate possible changes in the potential effects under varying 
assumptions for the vaccine-related parameters.
Rainisch et al. [22] compared the currently licensed mAb 
(palivizumab) with a hypothetical and more effective anti-
body for passive immunisation of infants in the USA. Using 
a static model, the authors assessed the effects of passive 
immunisation, applying different effectiveness and uptake 
parameters. Targeting all infants with an antibody candi-
date that was 80% effective against LRTIs and provided 150 
days of induced immunity led to reductions of cases attend-
ing outpatient clinics by 48%, hospitalisations by 55%, and 
emergency care by 51%.
Similarly, using a cohort model, Li et al. [40] evaluated 
the immunisation of infants with a mAb candidate in 72 
Gavi-supported countries and compared it with the maternal 
strategy. For 70% effective mAb with 6 months of induced 
immunity, they showed an average of a 23% reduction in 
RSV hospitalisations in those countries, though the esti-
mates of the averted burden of the disease varied consider-
ably between the countries. The results indicated that the 
assumed additional month of mAb-induced protection led 
to prevention of more cases, hospitalisation, and deaths than 
the maternal vaccine. The economic evaluation resulted in 
potential cost-effectiveness ratios ranging from $US3260 
(for Angola) to $US8198 (for Vietnam) PPP 2018 per DALY 
averted compared with no intervention. Passive immunisa-
tion ($US6.2 PPP 2018/dose) will potentially be an optimal 
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strategy if the WTP value is higher than $US6000 ($US6205 
PPP 2018) per DALY. The price difference between the 
maternal vaccine and the mAb influences the choice of 
optimal intervention. The study indicated that, if an addi-
tional month of protection were worth more than $US1, the 
potential optimal strategy would be passive immunisation 
for all countries.
Three other studies [30, 32, 35] reported health economic 
estimates of infant vaccination strategies (see Table 4). The 
cost per QALY gained ranged from $US48,566 to 83,357 
PPP 2018, and the maximum cost-effective price per fully 
protected person was estimated as $US290 PPP 2018 (rela-
tive to the UK National Institute for Care and Excellence 
cost-effectiveness threshold). These studies reported health 
economic estimates of a large set of infant strategies, varying 
age at vaccination, efficacy, and uptake parameters.
The lowest cost per QALY gained was estimated by Meij-
boom et al. [30] for vaccinating infants at 0, 1, and 3 months 
of age with a vaccine with long-lasting protection (10 years). 
The authors assumed increasing VE for each subsequent 
dose, i.e. 30%, 60%, and 75%, respectively. A 66.5% reduc-
tion in hospitalisations was estimated for this scenario. The 
study showed that vaccination at the earliest possible age 
brought more health benefits. Delay in the administration 
of succeeding doses increased the ICER. Waning vaccine-
induced immunity decreased health outcomes and increased 
the cost-effectiveness estimates.
Pouwels et al. [35] considered vaccination at ages 2 and 
4 months assuming increased effectiveness of the second 
dose (60 and 75%, respectively). A strategy with 85% cover-
age and an 8-month duration of vaccine-induced immunity 
resulted in a 42% reduction in hospitalisations and a gain 
of 2172 discounted QALYs for a cost of $US49,018 PPP 
2018/QALY.
Cromer et al. [32] reported that infant vaccination at 3 
months of age resulted in 62% averted hospitalisations and 
95% prevented outpatient visits. Most of the 73% QALY gain 
associated with this strategy was achieved via the reduction 
of cases in primary care. The assumptions included 70% 
(50–100%) VE and immunity lasting for 5 years. Seasonal 
immunisation strategies to protect newborns and infants 
were shown to be potentially cost effective. In particular, 
restricting passive prophylaxis to infants born before the 
peak of the RSV season (in November in England) was the 
most cost-effective strategy.
3.7  Vaccination of Young Children
Vaccination of children aged < 5 years [24] and vaccination 
of school-aged children [3] are proposed alternatives to pro-
tect younger age groups. Yamin et al. [24] characterised the 
vaccination of children aged 6 months to 5 years as highly 
effective. For VE of 80% with a duration of protection over 
one season, they predicted the reduction of 0.1–0.5 RSV 
cases per dose in children and 0.1–0.4 cases per dose in 
adults aged ≥ 50 years. Poletti et al. [3] found that, over 10 
years, vaccination at school enrolment could reduce RSV 
incidence by 35.6% in infants and, additionally, by 40% in 
the general population because of herd effects. Under the 
assumption of 6-month vaccine-induced immunity, repeated 
vaccination of students was shown to be an effective alterna-
tive, although it would require a larger number of vaccine 
doses. There was no economic evaluation of vaccination of 
children in this review.
3.8  Vaccination of the Elderly
Yamin et al. [24] evaluated the epidemiological impact of 
targeting adults aged ≥ 50 years. One dose of RSV vac-
cine with VE of 80% given to adults aged ≥ 50 years was 
predicted to prevent 0.0036–0.0086 cases in the elderly and 
0.0001–0.0014 cases in children aged ≤ 5 years. The study 
showed that the direct effects of elderly vaccination were 
lower than the indirect effects of vaccinating children, even 
when VE was assumed to be the same in all age groups. Two 
economic evaluations [20, 29] suggested that vaccination 
in the elderly could be potentially cost effective depending 
on the vaccine characteristics and target population (ICER 
range $US6886.30–189,282.90 PPP 2018/QALY gained). 
However, the quality assessment demonstrated methodologi-
cal limitations in these studies.
3.9  Combined Vaccination Strategies
Cromer et al. [32] estimated that a combination of active 
infant vaccination at 3 months of age and passive newborn 
immunisation prevented around eight RSV cases per 100 
births with the maximum cost-effective price of $US371 
PPP 2018. Pouwels at el. [35] showed that vaccinating 
infants at 2 and 4 months of age as well as pregnant women 
prevented 54.2% of hospitalisations in infants and estimated 
an ICER of $US58,152 PPP 2018. Both studies indicated 
that the combination of maternal and infant strategies had 
a higher potential impact on RSV incidence in infants and 
children aged < 5 years but was less attractive from the cost-
effectiveness point of view.
4  Discussion
This systematic review summarises the current research 
activity in the assessment of the effectiveness and cost 
effectiveness of RSV vaccination strategies in the absence 
of clinical evidence. Although all studies demonstrated a 
considerable impact from vaccinating different sections 
of the population, the estimates varied considerably. The 
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review shows that the potential epidemiological impact 
largely depends on the modelling approaches, assump-
tions surrounding the epidemiology of RSV, and definition 
of vaccination scenarios. The economic outcomes were 
additionally driven by the economic inputs (e.g. assumed 
vaccine price, costs per RSV case, QALY decrements) and 
the choice of epidemiological endpoints. For example, the 
economic evaluations showed the importance of including 
outpatient care into the analysis. Careful consideration of 
adopted approaches to represent RSV epidemiology, health-
care utilisation, and vaccination impact at the population 
level is critical for the facilitation of decision making.
4.1  Model Structures and RSV Epidemiology
The static models can be a helpful initial estimation of the 
direct impact of vaccination on epidemiological outcomes 
for economic evaluations. This is particularly the case 
for maternal vaccination, which produces passive protec-
tion of newborns. However, they do not include potential 
protective effects in the unvaccinated groups of the popu-
lation. The dynamic models in this review differed in the 
assumptions surrounding the natural history of disease and 
vaccine effects, which influenced the epidemiological out-
comes. All of them assumed the SIRS structure but varied 
in the description of immunity due to maternal antibodies, 
the transmission of RSV by asymptomatic and reinfected 
groups, and the acquisition and duration of natural immu-
nity. These differences show the remaining gaps in knowl-
edge surrounding the age-dependent risk of RSV infection 
and its epidemiology in different population groups, which 
limits the modelling efforts.
In both high- and low-middle–income settings, the studies 
illustrate a critical lack of data on RSV incidence in chil-
dren. For Gavi-eligible countries, Li et al. [40] and Baral 
et al. [39] highlighted the essential gaps in data on RSV-
attributable hospitalisation and mortality rates and called for 
better evidence on RSV incidence and on the disease bur-
den for fine age strata. Other modelling studies that explore 
interventions in low-income settings used only the data from 
surveillance of children admitted to the Kilifi district hospi-
tal. In high-income settings, the researchers addressed the 
lack of data either by obtaining the data from observational 
studies or inferring the incidence and hospitalisation rates 
using data from different sources, such as administrative 
and laboratory data. It is important to note that only three 
studies in our review, all conducted in high-income settings, 
considered targeting the elderly for vaccination. Given the 
changing demographic structure in high-income countries 
and increasing evidence of the substantial impact of RSV 
in the elderly, further projections of the potential direct and 
indirect effects of prevention strategies are necessary. To 
facilitate model-based evaluations of prevention strategies, 
further estimates of the disease burden in the elderly, includ-
ing quality-of-life impairment, are needed, especially across 
health risk groups and in both nursing homes and the com-
munity. Overall, there is a need for epidemiological research 
on RSV transmission, especially within households, age- and 
period-stratified RSV incidence, hospitalisation rates, in-
hospital mortality, and reinfection rates in different settings. 
With regard to the latter, the dynamic-transmission models 
assume decreasing susceptibility with increasing age and 
levels of exposure. However, the current state of knowledge 
does not allow separation of the two effects within a model, 
and further epidemiological evidence is needed.
Additionally, the clinical context was not fully repre-
sented in the models, which reported mostly hospitalisations 
and infections. Clinical stages determined costs and health 
outcomes and constituted crucial inputs into the economic 
evaluations. Cromer et al. [32], for example, showed a non-
negligible contribution of primary care into resource utilisa-
tion attributable to RSV.
Further, only one study [23] in our selection considered 
asthma as a long-term complication of a severe RSV infec-
tion in infancy. Díez-Domingo et al. [44] presented evidence 
on the frequent occurrence of RSV-associated respiratory 
(and other) complications, such as asthma and COPD, later 
in life. Inclusion of the respective quality-of-life impairment 
and costs into models and evaluations of preventive strate-
gies will be informative.
4.2  RSV Vaccination
Estimation of vaccination impact strongly depended on the 
age at administration (and the health risk group), and the 
assumptions about VE, duration of vaccine-induced immu-
nity, and vaccine uptake. Although most of the studies pre-
sented the results across a wide range of VE parameters, the 
duration of vaccine-induced immunity varied between vac-
cine types. The most commonly used assumption was that 
immunity lasted over one season or for the same period as 
natural immunity. Other assumptions included long-lasting 
immunity with or without waning. These assumptions influ-
ence the effects of maternal vaccination and the optimal age 
of infant vaccination. The optimal age of vaccination could 
not be determined in this review. Most studies evaluated 
vaccination of infants aged 0–4 months, probably targeting 
the group with the highest numbers of RSV (severe) disease.
As most studies considered medically attended RSV 
infections as epidemiological outcomes, they applied VE as 
a reduction in primary infections and healthcare utilisation. 
However, because clinical evidence is currently not avail-
able, studying different vaccine characteristics can decrease 
uncertainty and provide better evidence for decision making. 
Pan-Ngum et al. [37], for example, showed that considera-
tion of VE against infectiousness and duration of infection 
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affected the clinical endpoints. The dynamic models also 
showed that assumptions about effective age-dependent 
contact rates influenced the magnitude of the vaccination 
effects, and the inclusion of households and schools into the 
models could facilitate a more targeted approach to develop-
ing vaccination strategies.
The vaccine uptake parameter influenced the effective-
ness and cost-effectiveness estimates. Some studies might 
have overestimated vaccine uptake, reaching over 90%, 
which contributed to the high impact of the vaccination. 
The values of vaccine uptake based on the observed rates 
for similar vaccinations were lower. Additionally, the num-
ber of vaccine doses influenced the cost of vaccination pro-
grammes and was important for the economic evaluations.
4.3  Epidemiological Outcomes
Most studies focused on the protection of newborns, neo-
nates, infants, and young children. Vaccination of the elderly 
is currently not well-examined as a strategy in models, 
although RSV impact in the elderly has been well-docu-
mented. The studies reviewed here predicted a considerable 
potential direct impact on RSV disease in infants associated 
with maternal vaccination and high-coverage active and pas-
sive immunisation of infants aged < 6 months in both high- 
and low-middle–income settings. Compared with maternal 
vaccination, infant strategies were considered more effec-
tive possibly because of the assumption of a longer-lasting 
immunity.
The dynamic models suggested beneficial indirect effects 
of vaccination of young children and school-aged children 
on RSV infections in infants and the elderly, but the indirect 
effects of maternal vaccination in children aged ≥ 6 months 
might be small. Yamin et al. [24] showed that infected chil-
dren aged < 5 years transmitted the infection to more than 
one individual. Infected older individuals, on the other hand, 
were less responsible for transmission than any other age 
group. Therefore, the models that applied restricted age 
structures likely underestimated the potential vaccination 
impact at the population level. In contrast, given the sug-
gested small herd effect of maternal vaccination, the applica-
tion of a limited age structure in modelling this intervention 
could be sufficient to estimate the vaccination impact. A 
more detailed social structure allowed modelling of more 
targeted vaccination scenarios. In Kenya, Poletti et al. [3] 
found that infant infections were caused by transmission 
within a household when infants cohabitated with one or 
more older siblings aged < 13 years. In these households, 
the school-age children were mainly responsible for intro-
ducing the infection and causing about half of the household 
outbreaks. Overall, vaccination of school-aged children and 
maternal vaccination, which can induce passive protection 
for 8 months, represented effective strategies when direct 
vaccination of newborns and infants was not achievable. 
Compared with the maternal vaccination in Poletti et al. 
[3] and using the data from the same source, Brand et al. 
[38] illustrated that additional reductions in hospitalisation 
of infants could be potentially achieved through a cocoon-
ing strategy, i.e. vaccinating pregnant women and the mem-
bers of their households. None of the studies in our review 
explored RSV transmission within households in high-
income settings.
Combining vaccination groups can increase the potential 
benefits, but it may be less cost effective. Current evidence 
on possible combinations of vaccination programmes is 
scarce. The combination of maternal vaccination and pas-
sive immunisation of infants can be considered as an alterna-
tive to direct vaccination of infants. Three studies [22, 32, 
40] evaluated the potential impact of passive immunisation 
with novel mAbs, indicating a further need in assessing the 
antibody candidates currently under development.
Further, the results suggest that consideration of RSV 
seasonality is important for the development of a vaccina-
tion policy. The dynamic models incorporated increased 
transmission during the RSV season. Therefore, restricting 
vaccination to children born before the beginning and peak 
of the RSV season can be more effective. The seasonal peaks 
differed between the studies, supporting the statement that 
RSV seasonality is related to climate. Therefore, the devel-
opment of an optimal vaccination strategy needs careful con-
sideration of country-specific RSV epidemiology.
4.4  Economic Outcomes
Half of the reviewed studies analysed the economic out-
comes of RSV vaccination. Most studies used static mod-
els to investigate cost effectiveness. The reported estimates 
included cost per gained health outcome such as QALY and 
cost per averted healthcare service. Other estimates, such as 
the maximum cost-effective price per fully protected person 
and the break-even costs calculated for a wide range of vac-
cination scenarios, can guide decision making and vaccine 
development. Overall, the results indicate that RSV vaccina-
tion of different groups would be cost effective; however, the 
epidemiological analyses suggest that infant and childhood 
vaccinations contribute more health benefits than maternal 
vaccination in protecting children. That might be because of 
the assumption of longer-lasting vaccine-induced immunity 
in infants.
For high-, middle-, and low-income countries, the cost 
effectiveness of maternal vaccination depends on WTP. 
In Gavi-supported countries, when WTP is lower than 
$US1000/DALY, no intervention is optimal. For WTP 
above $US1000, maternal vaccination becomes cost effec-
tive, and passive infant immunisation is cost effective only 
when WTP is above $US3500. Although WTP values differ 
Effects of Active Immunisation against RSV using Decision-Analytic Models
considerably between high- and low-income countries, a 
similar pattern can be seen in the results by Cromer et al. 
[32] for England. The study reported a lower maximum cost-
effective price for maternal vaccination than for passive or 
active infant immunisation. These evaluations pointed out 
that maternal and infant strategies should be competitively 
priced to be considered good value for money. Cocooning 
strategies have not been economically evaluated and need to 
be looked at in further research.
The effectiveness and cost effectiveness of potential 
elderly vaccination need further exploration, preferably 
using dynamic-transmission models in the settings of child-
hood immunisation. The indirect protection of the elderly 
might reduce the economic suitability of vaccination in the 
elderly. Additionally, the review shows a need for further 
measurement and analysis of health-related quality of life 
of patients with RSV across the age and disease severity 
groups. Also, the possible impact of vaccination on RSV-
induced long-term conditions, such as asthma, requires 
further investigation and inclusion in economic evalua-
tions. Further, the chosen comparator in most of the studies 
reviewed was no vaccination, whereas if passive immunisa-
tion with palivizumab were in place, it would reduce the 
RSV incidence and hence the beneficial impact of vaccina-
tion [32] in infants. Therefore, the consideration and inclu-
sion of current practice in economic analysis is necessary.
Lastly, a thorough examination of uncertainty is benefi-
cial for decision making. Current studies demonstrate the 
influence of the following inputs on the performance of vac-
cination: RSV incidence and distribution of RSV burden 
over the age groups, vaccine characteristics, vaccine uptake 
and vaccination age, duration of natural maternally derived 
protection and natural immunity, cost-related parameters 
(including vaccine price), and QALY losses. These elements 
require careful analysis to interpret the findings of economic 
evaluations.
4.5  Limitations of This Review
The review was restricted to peer-reviewed publications 
exploring active immunisation against RSV. Therefore, it 
does not provide any new evidence on the evaluation of pas-
sive immunisation of infants with palivizumab, which might 
have been published after publication of the review on its 
cost effectiveness [17]. Regarding the quality assessment, 
the appraisal was performed using the EVIDEM instru-
ment, which was not initially intended for the evaluation 
of methods used for the simulation of infectious diseases. 
Nonetheless, EVIDEM enabled a transparent and thorough 
appraisal of the methodological approaches and assump-
tions, which was performed by two reviewers independently 
and described in the EVIDEM forms available in ESM 2. 
Overall, the synthesis of evidence presented in this review 
posed more difficulties than usually expected in this type 
of study because of the vast range of studied vaccination 
strategies and considerable methodological differences in 
modelling RSV epidemiology and vaccine effects.
5  Conclusion
This review indicates that, if clinical estimates of effective-
ness and vaccine-induced protection, as well as actual vac-
cination uptake rates, are close to the values assumed in the 
modelling studies, maternal and infant RSV interventions 
will prevent a sizeable number of RSV-related severe and 
non-severe LRTIs in children. Maternal vaccination can be 
considered a feasible and less expensive strategy to protect 
infants in the first months of life. If the vaccine-induced 
immunity is short lasting, infant immunisation or a combina-
tion of infant and maternal vaccination might be examined 
for implementation. In the case of infant vaccination, in 
countries where surges in RSV cases follow seasonal pat-
terns, immunisation before and during an RSV season might 
be preferred. Further modelling-based evaluations of a wider 
range of scenarios, including maternal, seasonal, cocoon-
ing, and elderly strategies for varying coverage rates will be 
beneficial for decision making.
Currently, studies investigating the epidemiological and 
economic impacts of vaccinating different population groups 
against RSV based on a dynamic-transmission model are 
lacking. The availability of age-specific epidemiological, 
clinical, and health economic data restricts the development 
of the mathematical models and limits model-based health 
economic analyses. To reduce decision uncertainty and facil-
itate more conclusive evaluations, epidemiological research 
and the estimation of RSV cases and hospitalisations for 
fine age strata is required. Additionally, natural immunity, 
reinfections, and household contacts in the transmission of 
RSV infections needs further investigation.
Declarations 
Funding Open Access funding enabled and organized by Projekt 
DEAL. This research was supported by the Innovation Fund of the 
Joint Federal Committee (grant number 01VSF18015).
Conflict of Interest Marina Treskova, Francisco Pozo-Martin, Stefan 
Scholz, Viktoria Schönfeld, Ole Wichmann, and Thomas Harder have 
no conflicts of interest that are directly relevant to the content of this 
article.
Ethics approval Not applicable.
Availability of Data and Material The data presented in this review 
were obtained from the included studies, which are cited in the main 
and supplemental text. All other data generated during the review are 
presented in the tables in the review.
 M. Treskova et al.
Consent toparticipate Not applicable.
Consent for publication Not applicable.
Code Availability Not applicable.
Author Contributions All authors contributed to the conception of the 
study, the search and selection strategies, and the interpretation of the 
results. MT, FPM, STS, and VS conducted the searches, selected the 
studies, extracted the data and evaluated the quality. MT and FPM 
drafted the manuscript, with input from VS, TH, and OW. STS, VS, 
TH, and OW critically revised the manuscript and contributed to the 
final draft. All authors read and approved the final manuscript.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder. To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. Collins CL, Pollard AJ. Respiratory syncytial virus infections 
in children and adults. J Infect. 2002;45(1):10–7. https ://doi.
org/10.1053/jinf.2001.1016.
 2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary 
infection and reinfection with respiratory syncytial virus. Am 
J Dis Child. 1986;140(6):543–6. https ://doi.org/10.1001/archp 
edi.1986.02140 20005 3026.
 3. Poletti P, Merler S, Ajelli M, Manfredi P, Munywoki PK, James 
Nokes D, et al. Evaluating vaccination strategies for reducing 
infant respiratory syncytial virus infection in low-income settings. 
BMC Med. 2015. https ://doi.org/10.1186/s1291 6-015-0283-x.
 4. Sommer C, Resch B, Simoes EA. Risk factors for severe respiratory 
syncytial virus lower respiratory tract infection. Open Microbiol J. 
2011;5:144–54. https ://doi.org/10.2174/18742 85801 10501 0144.
 5. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, 
Gessner BD, et al. Global, regional, and national disease burden 
estimates of acute lower respiratory infections due to respiratory 
syncytial virus in young children in 2015: a systematic review 
and modelling study. Lancet. 2017;390(10098):946–58. https ://
doi.org/10.1016/s0140 -6736(17)30938 -8.
 6. Resch B. Burden of respiratory syncytial virus infection in young 
children. World J Clin Pediatr. 2012;1(3):8–12. https ://doi.
org/10.5409/wjcp.v1.i3.8.
 7. Resch B. respiratory syncytial virus infection in high-risk 
infants—an update on Palivizumab prophylaxis. Open Microbiol 
J. 2014;8:71–7. https ://doi.org/10.2174/18742 85801 40801 0071.
 8. Mejias A, Wu B, Tandon N, Chow W, Varma R, Franco E, et al. 
Risk of childhood wheeze and asthma after respiratory syncyt-
ial virus infection in full-term infants. Pediatr Allergy Immunol. 
2020;31(1):47–56. https ://doi.org/10.1111/pai.13131 .
 9. Priante E, Cavicchiolo ME, Baraldi E. RSV infection and respira-
tory sequelae. Minerva Pediatr. 2018;70(6):623–33. https ://doi.
org/10.23736 /s0026 -4946.18.05327 -6.
 10. Gonik B. The burden of respiratory syncytial virus infection in 
adults and reproductive-aged women. Glob Health Sci Pract. 
2019;7(4):515–20. https ://doi.org/10.9745/GHSP-D-19-00121 .
 11. Pastula ST, Hackett J, Coalson J, Jiang X, Villafana T, Ambrose 
C, et al. Hospitalizations for respiratory syncytial virus among 
adults in the United States, 1997–2012. Open forum Infect Dis. 
2017. https ://doi.org/10.1093/ofid/ofw27 0.
 12. Haber N. Respiratory syncytial virus infection in elderly adults. 
Med Mal Infect. 2018;48(6):377–82. https ://doi.org/10.1016/j.
medma l.2018.01.008.
 13. Falsey AR, Walsh EE. Respiratory syncytial virus infection in 
elderly adults. Drugs Aging. 2005;22(7):577–87. https ://doi.
org/10.2165/00002 512-20052 2070-00004 .
 14. Smithgall M, Maykowski P, Zachariah P, Oberhardt M, Vargas 
CY, Reed C, et al. Epidemiology, clinical features, and resource 
utilization associated with respiratory syncytial virus in the com-
munity and hospital. Influ Other Respir Viruses. 2020;14(3):247–
56. https ://doi.org/10.1111/irv.12723 .
 15. Slifka MKA. Passive immunization. Plotkin’s vaccines. 7th ed. 
Amsterdam: Elsevier; 2017. p. 84–95.
 16. Siegrist CA. Vaccine immunology. Plotkin’s vaccines. 7th ed. 
Amsterdam: Elsevier; 2017. p. 16–34.
 17. Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, 
Sander B. Cost-effectiveness of Palivizumab for respiratory syn-
cytial virus: a systematic review. Pediatrics. 2019. https ://doi.
org/10.1542/peds.2018-4064.
 18. Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, 
Horsley N, et al. The respiratory syncytial virus vaccine land-
scape: lessons from the graveyard and promising candidates. 
Lancet Infect Dis. 2018;18(10):e295–311. https ://doi.org/10.1016/
s1473 -3099(18)30292 -5.
 19. Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, 
Rindress D. Evidence and Value: Impact on DEcisionMaking—
the EVIDEM framework and potential applications. BMC Health 
Serv Res. 2008;8:270. https ://doi.org/10.1186/1472-6963-8-270.
 20. Gessner BD. The cost-effectiveness of a hypothetical respiratory 
syncytial virus vaccine in the elderly. Vaccine. 2000;18(15):1485–
94. https ://doi.org/10.1016/S0264 -410X(99)00425 -9.
 21. Nugraha ES, Nuraini N. Simple vaccination and preven-
tion model of respiratory syncytial virus. Far East J Math Sci. 
2017;102(9):1865–80. https ://doi.org/10.17654 /MS102 09186 5.
 22. Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the 
impact of multiple immunization products on medically-attended 
respiratory syncytial virus (RSV) infections in infants. Vaccine. 
2020;38(2):251–7. https ://doi.org/10.1016/j.vacci ne.2019.10.023.
 23. Régnier SA. Respiratory syncytial virus immunization program 
for the United States: impact of performance determinants of a 
theoretical vaccine. Vaccine. 2013;31(40):4347–54. https ://doi.
org/10.1016/j.vacci ne.2013.07.024.
 24. Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, 
Townsend JP, et al. Vaccination strategies against respiratory syn-
cytial virus. Proc Natl Acad Sci USA. 2016;113(46):13239–44. 
https ://doi.org/10.1073/pnas.15225 97113 .
 25. Acedo L, Díez-Domingo J, Moraño JA, Villanueva RJ. Math-
ematical modelling of respiratory syncytial virus (RSV): vac-
cination strategies and budget applications. Epidemiol Infect. 
2010;138(6):853–60. https ://doi.org/10.1017/S0950 26880 99913 73.
 26. Acedo L, Moraño JA, Díez-Domingo J. Cost analysis of a vaccina-
tion strategy for respiratory syncytial virus (RSV) in a network 
model. Math Comput Model. 2010;52(7–8):1016–22. https ://doi.
org/10.1016/j.mcm.2010.02.041.
 27. Jornet-Sanz M, Corberán-Vallet A, Santonja FJ, Villanueva RJ. A 
Bayesian stochastic SIRS model with a vaccination strategy for the 
analysis of respiratory syncytial virus. SORT. 2017;41(1):159–76.
 28. Bos JM, Rietveld E, Moll HA, Steyerberg EW, Luytjes W, 
Wilschut JC, et al. The use of health economics to guide drug 
Effects of Active Immunisation against RSV using Decision-Analytic Models
development decisions: determining optimal values for an RSV-
vaccine in a model-based scenario-analytic approach. Vac-
cine. 2007;25(39–40):6922–9. https ://doi.org/10.1016/j.vacci 
ne.2007.07.006.
 29. Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV 
vaccine in development: Assessing the potential cost-effectiveness 
in the Dutch elderly population. Vaccine. 2013;31(52):6254–60. 
https ://doi.org/10.1016/j.vacci ne.2013.10.023.
 30. Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, 
Kneyber MCJ, Wilschut JC, et al. Cost-effectiveness of potential 
infant vaccination against respiratory syncytial virus infection in 
The Netherlands. Vaccine. 2012;30(31):4691–700. https ://doi.
org/10.1016/j.vacci ne.2012.04.072.
 31. van Boven M, Teirlinck AC, Meijer A, Hooiveld M, van Dorp CH, 
Reeves RM, et al. Estimating transmission parameters for respira-
tory syncytial virus and predicting the impact of maternal and 
pediatric vaccination. J Infect Dis. 2020. https ://doi.org/10.1093/
infdi s/jiaa4 24.
 32. Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Bur-
den of paediatric respiratory syncytial virus disease and poten-
tial effect of different immunisation strategies: a modelling 
and cost-effectiveness analysis for England. Lancet Public 
Health. 2017;2(8):e367–74. https ://doi.org/10.1016/S2468 
-2667(17)30103 -2.
 33. Kinyanjui T, Pan-Ngum W, Saralamba S, Taylor S, White L, 
Nokes DJ. Model evaluation of target product profiles of an infant 
vaccine against respiratory syncytial virus (RSV) in a developed 
country setting. Vaccine X. 2020. https ://doi.org/10.1016/j.jvacx 
.2020.10005 5.
 34. Hogan AB, Campbell PT, Blyth CC, Lim FJ, Fathima P, Davis 
S, et al. Potential impact of a maternal vaccine for RSV: a math-
ematical modelling study. Vaccine. 2017;35(45):6172–9. https ://
doi.org/10.1016/j.vacci ne.2017.09.043.
 35. Pouwels KB, Bozdemir SE, Yegenoglu S, Celebi S, McIntosh 
ED, Unal S, et al. Potential cost-effectiveness of RSV vaccination 
of infants and pregnant women in Turkey: An illustration based 
on bursa data. PLoS ONE. 2016. https ://doi.org/10.1371/journ 
al.pone.01635 67.
 36. Kinyanjui TM, House TA, Kiti MC, Cane PA, Nokes DJ, Medley 
GF. Vaccine induced herd immunity for control of respiratory 
syncytial virus disease in a low-income country setting. PLoS 
ONE. 2015. https ://doi.org/10.1371/journ al.pone.01380 18.
 37. Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint JF, 
Saralamba S, et al. Predicting the relative impacts of maternal 
and neonatal respiratory syncytial virus (RSV) vaccine target 
product profiles: a consensus modelling approach. Vaccine. 
2017;35(2):403–9. https ://doi.org/10.1016/j.vacci ne.2016.10.073.
 38. Brand SPC, Munywoki P, Walumbe D, Keeling MJ, Nokes DJ. 
Reducing RSV hospitalisation in a lower-income country by vac-
cinating mothers-to-be and their households. eLife. 2020. https ://
doi.org/10.7554/eLife .47003 .
 39. Baral R, Li X, Willem L, Antillon M, Vilajeliu A, Jit M, et al. 
The impact of maternal RSV vaccine to protect infants in 
Gavi-supported countries: Estimates from two models. Vac-
cine. 2020;38(33):5139–47. https ://doi.org/10.1016/j.vacci 
ne.2020.06.036.
 40. Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health 
and economic burden of respiratory syncytial virus (RSV) disease 
and the cost-effectiveness of potential interventions against RSV 
among children under 5 years in 72 Gavi-eligible countries. BMC 
Medicine. 2020. https ://doi.org/10.1186/s1291 6-020-01537 -6.
 41. Weber A, Weber M, Milligan P. Modeling epidemics caused by 
respiratory syncytial virus (RSV). Math Biosci. 2001;172(2):95–
113. https ://doi.org/10.1016/S0025 -5564(01)00066 -9.
 42. Roy LMC, Bansback N, Marra C, Carr R, Chilvers M, Lynd 
LD. Evaluating preferences for long term wheeze follow-
ing RSV infection using TTO and best-worst scaling. Allergy 
Asthma Clin Immunol. 2014;10(Suppl 1):A64-A. https ://doi.
org/10.1186/1710-1492-10-S1-A64.
 43. Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state 
valuations for pertussis: methods for valuing short-term health 
states. Health Qual Life Outcomes. 2005;3:17. https ://doi.
org/10.1186/1477-7525-3-17.
 44. Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, 
Aguilar MD, Blasco AJ, et al. Social, economic, and health impact 
of the respiratory syncytial virus: a systematic search. BMC Infect 
Dis. 2014;14(1):544. https ://doi.org/10.1186/s1287 9-014-0544-x.
 45. Rietveld E, De Jonge HC, Polder JJ, Vergouwe Y, Veeze HJ, Moll 
HA, et al. Anticipated costs of hospitalization for respiratory syn-
cytial virus infection in young children at risk. Pediatr Infect Dis 
J. 2004;23(6):523–9. https ://doi.org/10.1097/01.inf.00001 29690 
.35341 .8d.
 46. Nokes DJ, Ngama M, Bett A, Abwao J, Munywoki P, English 
M, et al. Incidence and severity of respiratory syncytial virus 
pneumonia in rural Kenyan children identified through hospital 
surveillance. Clin Infect Dis. 2009;49(9):1341–9. https ://doi.
org/10.1086/60605 5.
 47. Falsey AR, McCann RM, Hall WJ, Tanner MA, Criddle MM, 
Formica MA, et al. Acute respiratory tract infection in daycare 
centers for older persons. J Am Geriatr Soc. 1995;43(1):30–6. 
https ://doi.org/10.1111/j.1532-5415.1995.tb062 38.x.
 48. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory 
infections in the institutionalized elderly: clinical and epidemio-
logic findings. J Am Geriatr Soc. 1992;40(2):115–9. https ://doi.
org/10.1111/j.1532-5415.1992.tb019 29.x.
 49. Jackson MM, Fierer J, Barrett-Connor E, Fraser D, Klauber 
MR, Hatch R, et al. Intensive surveillance for infections in a 
three-year study of nursing home patients. Am J Epidemiol. 
1992;135(6):685–96. https ://doi.org/10.1093/oxfor djour nals.aje.
a1163 48.
 50. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral 
infections of upper respiratory tract in elderly people living in 
the community: comparative, prospective, population based study 
of disease burden. BMJ. 1997;315(7115):1060–4. https ://doi.
org/10.1136/bmj.315.7115.1060.
 51. Jansen AG, Sanders EA, Wallinga J, Groen EJ, van Loon AM, 
Hoes AW, et al. Rate-difference method proved satisfactory in 
estimating the influenza burden in primary care visits. J Clin 
Epidemiol. 2008;61(8):803–12. https ://doi.org/10.1016/j.jclin 
epi.2007.08.017.
 52. Wilfret DA, Baker BT, Palavecino E, Moran C, Benjamin DK Jr. 
Epidemiology of respiratory syncytial virus in various regions 
within North Carolina during multiple seasons. N C Med J. 
2008;69(6):447–52.
 53. Ohuma EO, Okiro EA, Ochola R, Sande CJ, Cane PA, Medley GF, 
et al. The natural history of respiratory syncytial virus in a birth 
cohort: the influence of age and previous infection on reinfection 
and disease. Am J Epidemiol. 2012;176(9):794–802. https ://doi.
org/10.1093/aje/kws25 7.
 54. Hacimustafaoglu M, Celebi S, Bozdemir SE, Ozgur T, Ozcan I, 
Guray A, et al. RSV frequency in children below 2 years hos-
pitalized for lower respiratory tract infections. Turk J Pediatr. 
2013;55(2):130–9.
 55. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of 
respiratory syncytial virus-related illness in the US: an analysis 
of national databases. Pharmacoeconomics. 2004;22(5):275–84. 
https ://doi.org/10.2165/00019 053-20042 2050-00001 .
